Buybacks have started to slide, which could be a concern for the market. Is Fed fear to blame?» Read More
Will M&A activity boost biotech stocks in 2009?
Stocks snapped a three-day winning streak Monday as traders cashed in some of their chips from last week's rally following some dismal reports on the telecom and financial sectors.
Stocks turned mixed Monday, the second day of trading in the new year, as a construction report came in much better than expected, as did U.S. auto sales. Stocks started off the day sharply lower as investors cashed in some of their chips after last week's rally that pushed the Dow up more than 6 percent and past the key 9,000 mark.
Biotechnology stocks are getting a lot of chatter already in this very young year.
The "Financial Times" apparently got a one-on-one interview with Pfizer Chairman and CEO Jeff Kindler and is playing up what he said with the headline, "Pfizer eyes merger deal with large rival."
Stocks declined Monday, the second day of trading in the new year, after a rally last week that pushed the Dow up more than 6 percent and past the key 9,000 mark. A report that showed construction spending fell by half of what was expected helped shave some of the loss.
We begin the "real" New Year with stocks at a 6-week high, and the S&P 500 24 percent above its November 20 low. Now let's see if we can change leadership: health care and consumer stocks have generally outperformed in the past few weeks, though recently industrial stocks have improved. A shift toward less defensive names would be a welcome development.
Wall Street looked set to open lower in the second day of trading of the year after Friday's rebound, with investors expected to take some profits following the Dow's rise to more than 9,000.
Everyone loves a winner. Following are the best performing stocks for 2008 for the Dow, Nasdaq and the S&P. But will they perform as well this year?
Now that 2008 is just about over, here's a look at the top yielding stocks in the Dow that would make up your portfolio if you followed the popular Dogs of the Dow investment strategy.
Merck, Lilly and Pfizer are all trading substantially higher. Will this bear market remedy keep working in the new year?
If you’re looking to put a little bite into your portfolio should you consider the "Dogs Of The Dow?"
Cramer makes the call on viewers' favorite stocks in a special, extended Lightning Round, including PepsiCo, Verizon, Baidu, Boeing and others.
As we head into the holiday break and the bloggable newsflow slows to a trickle, I am digging into the overflowing mailbag while filling in for my vacationing colleague Scott Wapner at the Nasdaq this week.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Some of the bad news Tuesday was "less worse" than many feared: Goldman Sachs reported its first quarterly loss since going public — but the $2.1 billion loss was much narrower than many had feared and Goldman shares rose as much as 11 percent. Stocks soared on the Federal Reserve rate-cut decision and options trading looks bullish on Boeing. CNBC heard from experts who predict a massive OPEC cut and more Fed moves to come.
Drugmaker Bristol-Myers Squibb said Tuesday it will eliminate another 10 percent of its work force through 2010 as it works to pare costs before it loses patent protection on key drugs.
We know all too well about the victims of the market's recent misfortunes, but what about those who have survived — and even thrived? Count Tom Forester and his five-star Forester Value Fund among those.
For months now several analysts have been pointing out that despite big pharma's many problems some of the companies still pay healthy dividends. And when T-bills are offering next to nothing, a solid dividend yield in these rough and tumble times is a good thing.
Pharma companies are usually considered safety plays. But might they also be growth stocks in disguise?